ACLX: Arcellx Corp Consensus Target

Symbol and logo of brand Arcellx Inc (ACLX)

Arcellx (ACLX) develops unique CAR-T therapies for hematological malignancies, where stringent FDA requirements and patent protection block the entry of new players. Massive expenditures on genetic research and regulatory oversight make the barrier to entry inaccessible for small firms. This chart reflects the current share price at 114.59. Capacity modernization and the operation of contract manufacturing sites guarantee a stable output of drugs.

Arcellx Inc - ACLX Consensus Target (period 04/28/2023 - 05/09/2026)

Analytical breakdowns for Arcellx Corp (ACLX)

- stock value and consensus price forecast:
Stock Price arcellx.com|ACLX - Analyst Consensus Forecast
- market capitalization information:
Market Valuation Arcellx Corp|ACLX - Total Company Value
- book value of equity indicators:
Net Assets per Single Share Arcellx|ACLX - Company Net Assets|Capitalization to Book Value Ratio arcellx.com|ACLX - Company Total Assets
- issuer credit burden and liquidity indicators:
Total Debt to Equity Ratio Arcellx|ACLX - Long-Term Debt to Capital|Short-Term Debt to Capital Arcellx Therapeutics|ACLX - Company Debts|Debt to Book Value Ratio Arcellx Corp|ACLX - Company Long-Term Debts|Company Current Liabilities Arcellx|Immediate Liquidity arcellx.com
- financial results and valuation multiples details:
ACLX - Company Net Income|Expected Net Income Arcellx|ACLX - Price to Earnings Ratio|Future Price to Earnings Multiple Arcellx Inc|ACLX - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Arcellx Corp|ACLX - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months Arcellx|ACLX - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months arcellx.com|ACLX - Earnings per share growth in current year|Expected net earnings per share growth next year Arcellx
Fundamental company analysis:arcellx.com (ACLX)
Original product of Arcellx Corp

The market audit of Arcellx (ACLX) is based on an assessment of the commercial potential of its patented anti-cancer therapy. The consensus forecast aggregates expert expectations, measuring the asset's fair value by discounting future cash flows from monopoly sales. By analyzing the changes in the consensus share price forecast on GURU.Markets, an investor can track the dynamics of the risk premium revision. This indicator synchronizes the biotech's intrinsic value with market realities, confirming the long-term stability of the capital.

Competing companies

Analyst Consensus Forecast tgtherapeutics.com (TGTX)|Analyst Consensus Forecast IRON (Disc Medicine)|SNDX - Consensus Target|KURA - Price Target Chart|ADCT: Price Target Chart|FHTX (foghorntx.com) - Consensus Target|Broker Consensus Forecast VOR|NKTX (Nkarta Inc.) - Analyst Consensus Forecast|Consensus Target Coeptis (COEP)|Analyst Consensus Forecast ATNM|Analyst Consensus Forecast Estrella Immunopharma Corp (ESLA)|Price Target Chart CASI Pharmaceuticals, Inc. CASI|MRKR: Broker Consensus Forecast|IN8bio - Analyst Consensus Forecast|Eterna Therapeutics (ERNA) - Consensus Target|GTBP: Analyst Consensus Forecast|Average Forecast Price Aptose Biosciences (APTO)|Price Target Chart Bio-Path Holdings|MEIP: Fair Value Consensus|Consensus Target VINC (Vincerx Pharma, Inc.)